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OBJECTIVES: To estimate resource use and costs associated
with a diagnostic workup for suspected breast cancer among
female Medicare beneﬁciaries. METHODS: We used Medicare
5% sample claims data to select non-HMO women 65 who
had either a suspicious mammogram (Group A) or signs or
symptoms of breast cancer (Group B), but no evidence of active
treatment of any prior cancer, in the ﬁrst 3 quarters of 2004. We
then measured their resource use and costs associated with a
pre-deﬁned set of relevant breast cancer diagnostic services.
RESULTS: Our sample included 45,978 women (19,769 Group
A, 26,209 Group B). On average, women presenting for a breast
cancer diagnostic workup received 1.4 diagnostic mammograms,
1.0 pathology services, 0.6 radiology services, and 0.5 other
breast imaging studies, among other services. The average cost of
a diagnostic workup—whether it eventuated in a breast cancer
diagnosis or not—was $361, and was nearly identical between
groups ($363 Group A vs. $359 Group B), although breast
biopsy was a more important determinant of costs for patients in
Group A. We estimate that Medicare spends approximately $649
million annually on diagnostic workups for women with
suspected breast cancer, and that false positive mammograms
result in costs of approximately $250 million. CONCLUSION:
Resource use and costs of diagnostic workups for women pre-
senting with suspicion of breast cancer are substantial.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a pro-
gressive disease newly diagnosed in approximately 50 patients a
year in Scotland. It is associated with signiﬁcant health and
economic burden. Dasatinib is a new treatment indicated for
patients with CML who failed imatinib therapy. The purpose of
this study was to estimate cost-effectiveness of dasatinib vs. ima-
tinib in patients with chronic phase CML resistant to imatinib
from the perspective of NHS Scotland. METHODS: A Markov
model was developed to estimate the lifetime costs and health
outcomes associated with dasatinib (140 mg/day) compared to
imatinib (800 mg/day) in chronic phase CML patients resistant
to imatinib therapy. Patients progress through the disease in
monthly cycles based on their initial best response to treatment:
no response, complete haematological response, partial or com-
plete cytogenetic response, as observed in a randomised Phase II
trial. The rate of progression was based upon estimates from
published literature. Utility values used were obtained using the
EQ-5D in a CML utility study based on patient’s current health
status and level of response. Resource use was estimated by
expert haematologist and unit costs were taken from national
databases. Costs and outcomes were discounted at 3.5% per
annum. One-way and probabilistic sensitivity analyses were con-
ducted to estimate the stability of the results. RESULTS: In
chronic phase CML, treatment with dasatinib resulted in 0.68
incremental life years, 0.63 incremental QALYs, and savings of
£10,579 over the patient’s lifetime compared to treatment with
imatinib. Treatment with the lower-cost dasatinib reduces overall
costs due to fewer patients progressing to the advanced (and
costly) stages of CML. The results were stable under a range of
sensitivity analyses. CONCLUSION: Compared to imatinib,
dasatinib is associated with increased effectiveness at a lower
cost; dasatinib is a dominant treatment option for patients with
chronic phase CML resistant to imatinib.
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OBJECTIVES: XELOX has been shown to be non inferior to
FOLFOX-6 and well tolerated as ﬁrst-line treatment for MCRC
in the phase III trial ML16987. The purpose of this study was to
assess, in the French setting, the cost of XELOX and to compare
it to that of FOLFOX-6. METHODS: A total of 306 patients
were randomized to receive either XELOX (n = 156: capecitab-
ine 1000 mg/m2 bid d1-14, oxaliplatin 130 mg/m2 d1, q3w) or
FOLFOX-6 (n = 150: oxaliplatin 100 mg/m2 d1 LV 400 mg/m2
2 h infusion then 5-FU 400 mg/m2 i.v. bolus then 2400–
3000 mg/m2 46 h infusion, q2w) for 6 months in a prospective,
randomized, multicenter, phase III study. A cost minimization has
been conducted from the French hospital perspective. The cost of
hospitalizations for chemotherapy administration were compiled
applying ofﬁcial tariffs of the national ‘PMSI’ database, directly
derived from the Diagnosis Related Group (DRG). RESULTS:
The ITT population comprises 306 patients (156 on XELOX,
150 on FOLFOX-6). Baseline characteristics were well balanced.
The number of total hospitalizations, deﬁned as the mean
number of times patients are hospitalized for all causes, was
6.5  2.6 and 9.5  4.1 for XELOX and FOLFOX-6, respec-
tively. Patients received an average of 6.1  2.4 cycles of XELOX
and 9.2  3.2 cycles of FOLFOX-6. The costs of hospitalization
for chemotherapy are available for 282 patients (142 in the
XELOX arm and 140 in the FOLFOX-6 arm). The average cost
of chemotherapy per cycle was €608  446 per patient in the
XELOX arm and €1043  787 per patient in the FOLFOX-6
arm (p < 0.001). The average total cost of chemotherapy
(all cycles) per patient was €3309  1963 for XELOX and
€8198  6909 for FOLFOX-6. XELOX is cost saving by €4,889
per patients for all cycles performed. CONCLUSION: XELOX is
cost saving as ﬁrst-line treatment for MCRC and appears to
decrease hospital resource consumption.
Abstracts A233
